Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of wild type KRAS in KRASMUT lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors.

Lung cancer (Amsterdam, Netherlands) - 1 Mar 2021

Liu Yan, Gao Galen F, Minna John D, Williams Noelle S, Westover Kenneth D

Abstract excerpt

OBJECTIVES: Wild type RAS (RASWT) suppresses the function of oncogenic RAS mutants (RASMUT) in laboratory models. Loss of RASWT, which we termed loss of heterozygosity (LOH) for any RAS (LAR) or LAKR in the context of KRAS (LOH at KRAS), is found in patients with RASMUT cancers. However, the incidence and prognostic significance of LAR has not been studied in modern patient cohorts. LAR or LAKR in RASMUT cancers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Fatty Acid Synthases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 33465697
DOI: 10.1016/j.lungcan.2020.12.032
PMCID: PMC7897317

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of wild type KRAS in KRASMUT lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors.PMID 33465697Read ↗

Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis.Semantic proximity Read ↗

The genetics and biology of KRAS in lung cancer.Semantic proximity Read ↗

Metabolic rewiring in mutant Kras lung cancer.Semantic proximity Read ↗

Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma.Semantic proximity Read ↗

Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo.Semantic proximity Read ↗

The mystery of oncogenic KRAS: Lessons from studying its wild-type counter part.Semantic proximity Read ↗

FLIP is essential for oncogenic <i>KRAS-</i> driven lung cancerSemantic proximity Read ↗

LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant NSCLC to combined KRASG12C + MCL-1 blockadeSemantic proximity Read ↗

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer.Semantic proximity Read ↗

A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-rasSemantic proximity Read ↗

Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells.Semantic proximity Read ↗

ELOVL6 activity attenuation induces mutant KRAS degradation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.